Research.Patient.info

Adenoid cystic carcinoma (ACC) research hub

1 indexed studies · 0 currently recruiting

authorisedHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic, adenoid cystic carcinoma.
This study is testing a new medicine, REM-422, for adults with a type of cancer called adenoid cystic carcinoma (ACC) that has come back or spread. It's an early-stage study to see if the drug is safe and how it works.
France